Research has shown that expressing a constitutively active form of IKKβ in T cells enhances NF-κB activity, promoting an anti-tumor response that depends on IFN-γ-producing tumor-specific CD8+ T cells (22), highlighting the therapeutic potential of acceleration the IKKβ/NF-κB axis to augment antitumor immunity. Here, CD8A is linked to neoplasm.